Toolkit
Latest project information
HTA - 16/112/08
Blinatumomab for treating acute lymphoblastic leukaemia for people with minimal residual disease activity in remission [ID1036]
Project title: Blinatumomab for treating acute lymphoblastic leukaemia for people with minimal residual disease activity in remission [ID1036]
Call to action: 16/112 Batch 51
Research type: Evidence Synthesis
Chief investigator: Professor Matt Stevenson
Contractor: The University of Sheffield
Cost: £65,625.00
Started: November 2017 | Status: Project complete
Links to project documentation
The links and documents below are related to this research and are added as and when they are produced over the life of the project. The information is provided by the researchers and some may have undergone varying editorial, production and publication models, which differ to NIHR Journals Library reports. Links are to both internal (NIHR) and external websites – the NIHR is not responsible for the content of external websites.
Background & Research Questions
Why the research is being done and what is being asked
Methods
How the research is being done
Publications & Outputs
What the research produced
Outcomes & Impact
What happened as a result of the research